First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
nSEPIA aims to bring structure to an area long dominated by subjectivity
AI-powered platform uses real-time emotion scanning and personalised interventions to make emotional wellness measurable and actionable
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
In his new role, Curtis will lead the formulation and execution of the company’s global technical strategy
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
CDSCO-cleared BSM-5700 series targets ICU, NICU, ER, OR and digital health integration under ABDM
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
Subscribe To Our Newsletter & Stay Updated
